Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis

被引：0
|
作者：
Sturm, A. [1 ]
Sebastian, S. [2 ]
Faye, A. S. [3 ]
Armuzzi, A. [4 ]
Buisson, A. [5 ]
Halfvarson, J. [6 ]
Zeissig, S. [7 ,8 ]
Kochar, B. [9 ]
Maier, S. [10 ]
Redondo, I [10 ]
Moses, R. E. [10 ]
Keohane, A. [11 ]
Watanabe, K. [12 ]
机构：
[1] DRK Kliniken Berlin Westend, Dept Gastroenterol, Berlin, Germany
[2] Hull Univ Teaching Hosp, IBD Unit, Kingston Upon Hull, England
[3] NYU Langone Hlth, Inflammatory Bowel Dis Ctr, New York, NY USA
[4] IRCCS Humanitas Res Hosp, IBD Ctr, Milan, Italy
[5] Univ Clermont Auvergne, CHU Clermont Ferrand, Serv Hepatogastroenterol, Inserm,3iHP, Clermont Ferrand, France
[6] Orebro Univ, Dept Gastroenterol, Orebro, Sweden
[7] Univ Med Greifswald, Dept Internal Med A, Greifswald, Germany
[8] Tech Univ TU Dresden, Med Fac, Dresden, Germany
[9] Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA USA
[10] Eli Lilly & Co, Lilly Immunol, Indianapolis, IN USA
[11] HaaPACS GmbH, Stat Europe, Schriesheim, Germany
[12] Univ Toyama, Dept Internal Med Inflammatory Bowel Dis, Toyama, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1263
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1089
引用
收藏
页码：i2005 / i2006
页数：2
相关论文
共 50 条
  • [21] Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
    Ernest-Suarez, Kenneth
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [22] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [23] Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis
    Panaccione, Remo
    Collins, Eric B.
    Melmed, Gil Y.
    Vermeire, Severine
    Danese, Silvio
    Higgins, Peter D. R.
    Kwon, Christina S.
    Zhou, Wen
    Ilo, Dapo
    Sharma, Dolly
    Gonzalez, Yuri Sanchez
    Wang, Si-Tien
    CROHNS & COLITIS 360, 2023, 5 (02)
  • [24] PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
    Kaplan, Jess
    Bousvaros, Athos
    Turner, Dan
    Dubinsky, Marla C.
    Komocsar, Wendy
    Larkin, Amy E.
    Johns, Jordan
    Zhang, Xin
    Little, Cheryl A.
    Crandall, Wallace
    Arora, Vipin
    Hyams, Jeffrey S.
    GASTROENTEROLOGY, 2023, 164 (06) : S169 - S169
  • [25] Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial
    Danese, Silvio
    Dignass, Axel
    Matsuoka, Katsuyoshi
    Ferrante, Marc
    Long, Millie
    Redondo, Isabel
    Gibble, Theresa Hunter
    Moses, Richard
    Morris, Nathan
    Li, Xingyuan
    Milch, Catherine
    Abreu, Maria T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S535 - S535
  • [26] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Betts, Keith
    Eren, Devrim
    Tang, Wenxi
    Yin, Lei
    Gupte-Singh, Komal
    GASTROENTEROLOGY, 2022, 162 (07) : S603 - S603
  • [27] Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
    D'Haens, Geert
    Higgins, Peter D. R.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard E.
    Redondo, Isabel
    Escobar, Rodrigo
    Gibble, Theresa Hunter
    Keohane, Anthony
    Morris, Nathan
    Zhang, Xin
    Arora, Vipin
    Kobayashi, Taku
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2335 - 2346
  • [28] Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment
    Sands, Bruce E.
    Kobayashi, Taku
    Wu, Jianmin
    Wang, Isabella Yali
    Zhu, Baojin
    Redondo, Isabel
    Peyrin-Biroulet, Laurent
    Walsh, Alissa
    Magro, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1042 - S1043
  • [29] Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
    Kobayashi, Taku
    Matsuoka, Katsuyoshi
    Watanabe, Mamoru
    Hisamatsu, Tadakazu
    Hirai, Fumihito
    Milata, Joe
    Li, Xingyuan
    Morris, Nathan
    Arora, Vipin
    Ishizuka, Tomoko
    Matsuo, Koji
    Satoi, Yoichi
    Milch, Catherine
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2024, 22 (02) : 172 - 185
  • [30] RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND
    Schreiber, Stefan
    Panaccione, Remo
    Parkes, Gareth C.
    Peyrin-Biroulet, Laurent
    Ferrante, Marc
    Hisamatsu, Tadakazu
    Siegmund, Britta
    Kalabic, Jasmina
    Levine, Phillip
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Cheng, Ling
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward V.
    Melmed, Gil
    Louis, Edouard
    GASTROENTEROLOGY, 2024, 166 (05) : S238 - S238
12345